Metformin Renal Dose Adjustment — Lactic Acidosis Risk

Determine metformin dose adjustment or contraindication based on eGFR to prevent metformin-associated lactic acidosis (MALA) in type 2 diabetes patients with renal impairment per KDIGO and FDA recommendations.

Weight
Height
Clinical Guidance

BMI is a screening measure of body size, not a direct measure of body fat. The standard WHO categories are underweight (<18.5), normal (18.5–24.9), overweight (25–29.9), and obese (≥30).

BMI can overestimate body fat in athletes with high muscle mass and underestimate it in older adults with low muscle mass. Interpret it alongside waist circumference and clinical context rather than as a standalone diagnosis.

⚕ Clinical Disclaimer: These calculators are for educational and reference purposes only. Always verify results with qualified clinical judgment and current clinical guidelines. Do not use as a sole basis for medical decisions.
Advertisement

How It Works

Determine metformin dose adjustment or contraindication based on eGFR to prevent metformin-associated lactic acidosis (MALA) in type 2 diabetes patients with renal impairment per KDIGO and FDA recommendations

Each component has a specific meaning:

  • EGFR — The egfr recorded for the scenario being assessed.

Note: Interpret the metformin renal dose result against the thresholds and context described above.

How to Use

Enter the eGFR for the scenario you are assessing. Determine metformin dose adjustment or contraindication based on eGFR to prevent metformin-associated lactic acidosis (MALA) in type 2 diabetes patients with renal impairment per KDIGO and FDA recommendations. Use the metformin renal dose result to inform your calculation.

Frequently Asked Questions